Paladin Wealth LLC Lowers Position in Pfizer Inc. $PFE

Paladin Wealth LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 56.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,864 shares of the biopharmaceutical company’s stock after selling 15,224 shares during the quarter. Paladin Wealth LLC’s holdings in Pfizer were worth $288,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Livelsberger Financial Advisory purchased a new position in shares of Pfizer in the second quarter worth $108,000. Goldstone Financial Group LLC raised its stake in Pfizer by 53.8% during the second quarter. Goldstone Financial Group LLC now owns 25,241 shares of the biopharmaceutical company’s stock valued at $641,000 after purchasing an additional 8,832 shares in the last quarter. Boltwood Capital Management raised its stake in Pfizer by 2.1% during the second quarter. Boltwood Capital Management now owns 57,854 shares of the biopharmaceutical company’s stock valued at $1,402,000 after purchasing an additional 1,205 shares in the last quarter. Quintet Private Bank Europe S.A. raised its stake in Pfizer by 30.2% during the second quarter. Quintet Private Bank Europe S.A. now owns 468,523 shares of the biopharmaceutical company’s stock valued at $11,357,000 after purchasing an additional 108,608 shares in the last quarter. Finally, Teamwork Financial Advisors LLC raised its stake in Pfizer by 28.8% during the second quarter. Teamwork Financial Advisors LLC now owns 64,438 shares of the biopharmaceutical company’s stock valued at $1,562,000 after purchasing an additional 14,398 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 3.8%

NYSE PFE opened at $23.91 on Monday. The company’s 50-day moving average price is $24.79 and its 200-day moving average price is $24.27. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market cap of $135.94 billion, a PE ratio of 12.72, a PEG ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer’s dividend payout ratio is presently 91.49%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PFE shares. Berenberg Bank decreased their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. HSBC reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Finally, Jefferies Financial Group increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.